α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib.
We showed that α-bisabolol is active against primary acute leukemia cells, including BCR-ABL(+) acute lymphoblastic leukemias (ALL). Here we studied the activity of α-bisabolol against BCR-ABL(+) cells using 3 cell lines (K562, LAMA-84, CML-T1) and 10 primary BCR-ABL(+) ALL samples. We found that: (...
Main Authors: | Massimiliano Bonifacio, Antonella Rigo, Emanuele Guardalben, Christian Bergamini, Elisabetta Cavalieri, Romana Fato, Giovanni Pizzolo, Hisanori Suzuki, Fabrizio Vinante |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3463553?pdf=render |
Similar Items
-
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells
by: Fato Romana, et al.
Published: (2011-04-01) -
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
by: Marianne G. Pouwer, et al.
Published: (2018-06-01) -
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
by: Groffen John, et al.
Published: (2007-10-01) -
The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.
by: Wiltrud Haaß, et al.
Published: (2012-01-01) -
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
by: Yunyi Kang, et al.
Published: (2014-01-01)